These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 1843912)

  • 1. [Value of vasodilator agents in the treatment of diseases with pulmonary hypertension caused by chronic obstructive lung diseases].
    Lewczuk J; Wrabec K
    Pneumonol Alergol Pol; 1991; 59(3-4):153-8. PubMed ID: 1843912
    [No Abstract]   [Full Text] [Related]  

  • 2. [Sublingual captopril: indications and advantages?].
    Meyer GJ
    Dtsch Med Wochenschr; 2000 Apr; 125 Suppl 1():S4. PubMed ID: 10818992
    [No Abstract]   [Full Text] [Related]  

  • 3. [Clinical and hemodynamic evaluation of 6-week treatment of pulmonary hypertension in chronic obstructive lung diseases (COLD) with low dose of prazosin].
    Lewczuk J; Spikowski J; Sobkowicz-Woźniak B; Porada A; Wrabec K; Trzesicka M; Piszko P; Palka PS; Szczygielski J
    Kardiol Pol; 1990; 33(6):358-64. PubMed ID: 2084301
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Advances in the drug therapy of pulmonary hypertension in patients with chronic obstructive pulmonary disease].
    Liu SZ; Chen WB
    Zhonghua Jie He He Hu Xi Za Zhi; 1991 Apr; 14(2):107-10. PubMed ID: 1831694
    [No Abstract]   [Full Text] [Related]  

  • 5. [Management of hypertension in patients with cerebrovascular disease].
    Tsuchihashi T
    Nihon Rinsho; 2004 Mar; 62 Suppl 3():460-4. PubMed ID: 15171416
    [No Abstract]   [Full Text] [Related]  

  • 6. Vasodilatory treatment of pulmonary hypertension.
    Widimský J
    Eur J Respir Dis; 1986 Mar; 68(3):161-6. PubMed ID: 2870937
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of pulmonary hypertension in patients with chronic obstructive pulmonary disease: position of vasodilators with special focus on urapidil.
    Adnot S; Samoyeau R; Weitzenblum E
    Blood Press Suppl; 1995; 3():47-57. PubMed ID: 8535542
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [The role of renin-angiotensin system in pathogenesis of pulmonary hypertension in patients with chronic obstructive pulmonary disease].
    Frangulian RR
    Klin Med (Mosk); 2000; 78(10):18-20. PubMed ID: 11220892
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Pulmonary hypertension and cor pulmonale caused by chronic obstructive lung disease; pathogenesis and treatment].
    Dees A; Heysteeg M; de Leeuw PW
    Ned Tijdschr Geneeskd; 1991 Jun; 135(25):1120-4. PubMed ID: 1857437
    [No Abstract]   [Full Text] [Related]  

  • 10. Hemodynamic and hemorrheologic effect of ligustrazini in chronic obstructive pulmonary disease with cor pulmonale.
    Peng W; Duan SF
    Chin Med J (Engl); 1987 Dec; 100(12):965-70. PubMed ID: 3133172
    [No Abstract]   [Full Text] [Related]  

  • 11. Use of pulsed-wave Doppler echocardiography to measure changes in MPAP. Is further validation required?
    Morrell NW
    Chest; 1997 May; 111(5):1469-70. PubMed ID: 9149625
    [No Abstract]   [Full Text] [Related]  

  • 12. Impact of sildenafil therapy on pulmonary arterial hypertension in adults with congenital heart disease.
    Lu XL; Xiong CM; Shan GL; Zhu XY; Wu BX; Wu GH; Liu ZH; Ni XH; Cheng XS; Gu Q; Zhao ZH; Zhang DZ; Li WM; Zhang C; Tian HY; Guo YJ; Guo T; Liu HM; Zhang WJ; Gu H; Huang SA; Chen JY; Wu WF; Huang K; Li JJ; He JG
    Cardiovasc Ther; 2010 Dec; 28(6):350-5. PubMed ID: 20637015
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Pharmacologic effects of peripheral vasodilators in patients with secondary pulmonary hypertension].
    Kukes VG; Tsoĭ AN; Abrosimov AG; Nasyrov ShN; Belov AM
    Klin Med (Mosk); 1989 May; 67(5):52-6. PubMed ID: 2671486
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Vasodilator drugs in chronic obstructive airways disease.
    Howard P
    Eur Respir J Suppl; 1989 Jul; 7():678s-681s. PubMed ID: 2679615
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Effects of tetrandrine on pulmonary hypertension in patients with chronic obstructive pulmonary disease].
    Kang J
    Zhonghua Jie He He Hu Xi Za Zhi; 1993 Feb; 16(2):93-4, 124. PubMed ID: 8221961
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effect of amlodipine on exercise-induced pulmonary hypertension and right heart function in patients with chronic obstructive pulmonary disease.
    Franz IW; Van Der Meyden J; Schaupp S; Tönnesmann U
    Z Kardiol; 2002 Oct; 91(10):833-9. PubMed ID: 12395224
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Refractory cardiopulmonary insufficiency and peripheral vasodilators].
    Kazanbiev NK; Magomedov AZ
    Sov Med; 1990; (2):23-7. PubMed ID: 2192475
    [No Abstract]   [Full Text] [Related]  

  • 18. Oral sildenafil prevents and reverses the development of pulmonary hypertension in monocrotaline-treated rats.
    Liu H; Liu ZY; Guan Q
    Interact Cardiovasc Thorac Surg; 2007 Oct; 6(5):608-13. PubMed ID: 17670742
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Vasodilator treatment in pulmonary hypertension].
    Zăgreanu I; Duncea C; Rusu D; Căpîlneanu R
    Rev Med Interna Neurol Psihiatr Neurochir Dermatovenerol Med Interna; 1987; 39(4):333-9. PubMed ID: 2894052
    [No Abstract]   [Full Text] [Related]  

  • 20. The effects of hydralazine on exercise capacity in pulmonary hypertension secondary to chronic obstructive pulmonary disease.
    Dal Nogare AR; Rubin LJ
    Am Rev Respir Dis; 1986 Mar; 133(3):385-9. PubMed ID: 3954247
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.